Lantheus Holdings LNTH Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Definity | $330.25M+3.9% | $317.79M+13.6% | $279.77M+14.2% | $244.99M+5.3% | |
| Licenseand Royalty Revenues | $34.04M+273% | $9.13M-72.6% | $33.36M-30.5% | $48.02M+93.2% | |
| Neuraceq | $51.45M— | —— | $0— | —— | |
| PYLARIFY | $989.12M-6.5% | $1.06B+24.3% | $851.3M+61.4% | $527.41M+1,115% | |
| Strategic Partnerships And Other | $59.38M+55.5% | $38.18M-26.4% | $51.88M+10.7% | $46.87M+85.3% | |
| Concentration Risk % by Product | |||||
| Definity | 21.4%+0.7pp | 20.7%-0.9pp | 21.6%-4.6pp | 26.2%-28.5pp | |
| PYLARIFY | 64.2%-4.8pp | 69%+3.3pp | 65.7%+9.3pp | 56.4%+46.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Lantheus Holdings break its business down?
- Lantheus Holdings (LNTH) reports revenue by product across 9 parts — Cardiology, Definity, Licenseand Royalty Revenues, Neuraceq and Neurology. Each is extracted from the segment footnotes and tracked over time.
- Where does Lantheus Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Lantheus Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
